. "Jandlov\u00E1, T\u00E1\u0148a" . . . . "We have investigated the capacity of cellular vaccines based on dendritic cells loaded with human HPV16 E6/E7 oncoprotein-derived peptides to induce immune responses in vitro and to elicit protective immunity in a murine experimental model mimicking human HPV16-associated carcinomas. We have found a good correlation between the vaccine efficacy in vitro, determined by chromium release cytotoxic tests, and the level of protection against tumour growth in immunization-challenge experiments. The results from both in vitro and in vivo experiments revealed that BMDC-based cellular vaccines pulsed with peptides, which exceed the length optimal for binding of the MHC class I and which harbour the Th epitope, are capable to elicit strong and protective CTL-based immunity against HPV16-associated MHC class I positive tumours" . "Na my\u0161\u00EDm experiment\u00E1ln\u00EDm modelu napodobuj\u00EDc\u00EDm lidsk\u00E9 karcinomy vyvolan\u00E9 HPV16 jsme zkoumali schopnost bun\u011B\u010Dn\u00FDch vakc\u00EDn zalo\u017Een\u00FDch na dendritick\u00FDch bunk\u00E1ch inkubovan\u00FDch s peptidy odvozen\u00FDmi z lidsk\u00FDch onkoprotein\u016F HPV16 E6/E7 vyvolat imunitn\u00ED odpov\u011B\u010F in vitro a vyvolat ochrannou imunitu. V imuniza\u010Dn\u00EDch/expozi\u010Dn\u00EDch experimentech jsme na\u0161li dobrou korelaci mezi \u00FA\u010Dinnost\u00ED vakc\u00EDn in vitro, ur\u010Denou cytotoxick\u00FDmi testy s uvol\u0148ov\u00E1n\u00EDm chr\u00F3mu, a \u00FArovn\u00ED ochrany proti n\u00E1dorov\u00E9mu r\u016Fstu. V\u00FDsledky experiment\u016F in vitro i in vito odhalily, \u017Ee bun\u011B\u010Dn\u00E9 vakc\u00EDny zalo\u017Een\u00E9 na dendritick\u00FDch bu\u0148k\u00E1ch z kostn\u00ED d\u0159en\u011B pulzovan\u00FDch s peptidy, kter\u00E9 p\u0159esahuj\u00ED d\u00E9lku optim\u00E1ln\u00ED pro vazbu MHC 1. t\u0159\u00EDdy a kter\u00E9 obsahuj\u00ED epitop Th, jsou schopn\u00E9 proti MHC I pozitivn\u00EDm n\u00E1dor\u016Fm vyvolan\u00FDm HPV16 vyvolat silnou a ochrannou imunitu zalo\u017Eenou na CTL"@cs . . "Reini\u0161, Milan" . "RIV/68378050:_____/04:00108994" . "10"^^ . "Indrov\u00E1, Marie" . "RIV/68378050:_____/04:00108994!RIV/2005/AV0/A23005/N" . "HPV16 E6/E7 peptides; dendritic cells; cytotoxic lymphocytes"@en . . "7"^^ . . "CZ - \u010Cesk\u00E1 republika" . "We have investigated the capacity of cellular vaccines based on dendritic cells loaded with human HPV16 E6/E7 oncoprotein-derived peptides to induce immune responses in vitro and to elicit protective immunity in a murine experimental model mimicking human HPV16-associated carcinomas. We have found a good correlation between the vaccine efficacy in vitro, determined by chromium release cytotoxic tests, and the level of protection against tumour growth in immunization-challenge experiments. The results from both in vitro and in vivo experiments revealed that BMDC-based cellular vaccines pulsed with peptides, which exceed the length optimal for binding of the MHC class I and which harbour the Th epitope, are capable to elicit strong and protective CTL-based immunity against HPV16-associated MHC class I positive tumours"@en . "Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects"@en . . "567335" . . "5"^^ . . "Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects" . "6" . . "Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects"@en . . "Vonka, V." . "50" . . . . . . . . . . . "184;193" . "[6843343BAA77]" . "0015-5500" . . "Imunogenicita HPV16 E6/E7 peptidov\u00FDch vakc\u00EDn odvozen\u00FDch z dendritick\u00FDch bun\u011Bk: aktivace a obrann\u00FD \u00FA\u010Dinek CTL"@cs . "Velek, Ji\u0159\u00ED" . . "P(GA301/01/0985), P(GA301/04/0492), P(KSK5011112), P(NC7148), P(NR7807), Z(AV0Z5052915)" . "Bieblov\u00E1, Jana" . . "Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects" . "Folia Biologica" . "Buben\u00EDk, Jan" . "Imunogenicita HPV16 E6/E7 peptidov\u00FDch vakc\u00EDn odvozen\u00FDch z dendritick\u00FDch bun\u011Bk: aktivace a obrann\u00FD \u00FA\u010Dinek CTL"@cs .